Business
Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast
The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click here to register There ...
About this update from Jaguar Health, Inc.
[{"type":"text","content":"The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click here to register","length":242,"tagName":"p"},{"type":"text","content":"There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management","length":219,"tagName":"p"},{"type":"text","content":"This data was presented at the Annual ELITE PED-GI Congress by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology and the primary investigator for this study","length":177,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / April 28, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that Jaguar is hosting an investor webcast on Wednesday, April 30, 2025 at 8:30 AM Eastern to review the initial results of the proof-of-concept (POC) investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer, Jaguar's plant-based anti-secretory prescription drug, in patients with the rare diseases microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) that were presented by Dr. Mohamad Miqdady on April 26, 2025 at the 11th Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates.","length":744,"tagName":"p"},{"type":"text","content":"The webcast will include commentary from the following KOLs:","length":60,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology who is Sheikh Khalifa Medical City's (SKMC) Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division, and the primary investigator for the ongoing exploratory, single-arm open label non-randomized trial of crofelemer in Abu Dhabi","length":333,"tagName":"p"}]},{"val":[{"type":"text","content":"Dr. Christos Tzivinikos, Founder of the Pediatric GI Department at Al Jalila Children's Specialty Hospital in Dubai, and an Adjunct Clinical Assistant Professor at Mohammed Bin Rashid University of Medicine and Hea...